JeanPierre Bizzari - Halozyme Therapeutics Independent Director
| HALO Stock | USD 38.97 0.26 0.67% |
Director
Dr. JeanPierre Bizzari, M.D. is an Independent Director of the Company. Dr. Bizzari provides our Board of Directors with over 30 years of clinical oncology and global drug approval strategy expertise. He retired from Celgene Corporation having served as Executive Vice President and Global Head of Oncology from October 2012 to December 2015 and as Senior Vice President for Clinical Development Oncology from 2008 to October 2012, and oversaw the development and approval of a number of leading oncology products including REVLIMID, VIDAZA, ISTODAX and ABRAXANE . Prior to 2008, Dr. Bizzari served as Vice President, Clinical Oncology Development for SanofiAventis where he oversaw the approval of Eloxatin, Taxotere and Elitek. Dr. Bizzari was also Vice President, Clinical Development Oncology for RhnePoulenc Rorer. Dr. Bizzari is a member of the Scientific Advisory Board of Frances National Cancer Institute. Dr. Bizzari has also been a member of the international scientific committee of the French National Cancer Research Institute since 2005 and the French National Cancer Institute since 2010. Dr. Bizzari also serves on the board of directors of Transgene SA, a biopharmaceutical company, and biotechnology companies Compugen Ltd., Pieris Pharmaceuticals, Inc. and Nordic Nanovector ASA. Within the past five years he also served on the board of directors of Celator Pharmaceuticals, Inc., a biopharmaceutical company, and iTeos Therapeutics S.A, a biotechnology company. He also serves as a board observer at Onxeo S.A. Dr. Bizzari is a Doctor of Medicine and a graduate of the Nice Medical School and a specialist in oncology . Dr. Bizzari was also an assistant in the medical oncology department at La PitiSalptrire hospital in Paris. since 2015.
| Age | 63 |
| Tenure | 9 years |
| Professional Marks | Ph.D |
| Address | 12390 El Camino Real, San Diego, CA, United States, 92130 |
| Phone | 858 794 8889 |
| Web | https://halozyme.com |
Halozyme Therapeutics Management Efficiency
The company has return on total asset (ROA) of 0.1189 % which means that it generated a profit of $0.1189 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 2.2207 %, meaning that it created $2.2207 on every $100 dollars invested by stockholders. Halozyme Therapeutics' management efficiency ratios could be used to measure how well Halozyme Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of April 2024, Return On Tangible Assets is likely to grow to 0.35. Also, Return On Capital Employed is likely to grow to 0.22. At this time, Halozyme Therapeutics' Return On Tangible Assets are very stable compared to the past year. As of the 24th of April 2024, Fixed Asset Turnover is likely to grow to 16.71, while Non Currrent Assets Other are likely to drop about 9 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Shehnaaz Suliman | Ultragenyx | 46 | |
| Rafaele Tordjman | Ascendis Pharma AS | 45 | |
| Timothy Chen | BeiGene | 60 | |
| Louis Lavigne | Alector | 69 | |
| Alan Garber | Exelixis | 62 | |
| Charles Cohen | Exelixis | 67 | |
| Thomas Malley | BeiGene | 49 | |
| Michael Narachi | Ultragenyx | 57 | |
| Liz Anderson | Biomarin Pharmaceutical | N/A | |
| Robert Hombach | Biomarin Pharmaceutical | 51 | |
| Lynn Seely | Blueprint Medicines Corp | 59 | |
| Perry Karsen | Agios Pharm | 59 | |
| William Waddill | Protagonist Therapeutics | 60 | |
| Alan Lewis | Biomarin Pharmaceutical | 71 | |
| Kristine Yaffe | Alector | N/A | |
| Phillip Sharp | Alnylam Pharmaceuticals | 73 | |
| Thamil Annamalai | Protagonist Therapeutics | 55 | |
| Paul Schimmel | Alnylam Pharmaceuticals | 77 | |
| Alec Machiels | Apellis Pharmaceuticals | 45 | |
| Edwin Graaf | Ascendis Pharma AS | 42 | |
| Lars Ekman | Ultragenyx | 68 | |
Management Performance
| Return On Equity | 2.22 | ||||
| Return On Asset | 0.12 |
Halozyme Therapeutics Leadership Team
Elected by the shareholders, the Halozyme Therapeutics' board of directors comprises two types of representatives: Halozyme Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Halozyme. The board's role is to monitor Halozyme Therapeutics' management team and ensure that shareholders' interests are well served. Halozyme Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Halozyme Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Matthew Posard, Director | ||
| Mark Esq, Senior Officer | ||
| Harry Leonhardt, Senior Vice President Chief Compliance Officer, General Counsel | ||
| Jim Mazzola, Vice President Corporate Communication & Investor Relations | ||
| Dimitrios Chondros, Senior Vice President Chief Commercial Officer | ||
| Randal Kirk, Independent Director | ||
| Mark Gergen, COO, Senior Vice President | ||
| Alison Armour, Senior Vice President - Research and Development | ||
| Gary Grote, Chief Officer | ||
| Helen Torley, President CEO, Director | ||
| Laurie Stelzer, CFO and Sr. VP | ||
| Jeffrey Henderson, Director | ||
| Kenneth Kelley, Independent Chairman of the Board | ||
| Amy Fox, Senior Resources | ||
| James Daly, Director | ||
| Athena Countouriotis, Chief Medical Officer | ||
| Todd Butler, VP CEO | ||
| Christopher Bryant, Chief Operations | ||
| Bernadette Connaughton, Director | ||
| Kristin Schwartzbauer, Head Quality | ||
| Benjamin Hickey, Chief Commercial Officer | ||
| Nicole LaBrosse, CFO Director | ||
| MD MBA, Chief Officer | ||
| Jim Daly, Director | ||
| Cortney MBA, Chief Officer | ||
| Kathryn Falberg, Independent Director | ||
| Connie Matsui, Independent Director | ||
| Al Kildani, Vice President Investor Relations & Corporate Communications | ||
| Michael LaBarre, Senior Officer | ||
| JeanPierre Bizzari, Independent Director | ||
| Steve MBBS, Chief Officer | ||
| Schond Greenway, Executive Director, Investor Relations & Strategy | ||
| MRCP B, CEO President | ||
| Tram Bui, Head Communications |
Halozyme Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Halozyme Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 2.22 | ||||
| Return On Asset | 0.12 | ||||
| Profit Margin | 0.34 % | ||||
| Operating Margin | 0.45 % | ||||
| Current Valuation | 6.14 B | ||||
| Shares Outstanding | 127.05 M | ||||
| Shares Owned By Insiders | 1.00 % | ||||
| Shares Owned By Institutions | 99.00 % | ||||
| Number Of Shares Shorted | 7.89 M | ||||
| Price To Earning | 60.08 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Halozyme Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Halozyme Stock analysis
When running Halozyme Therapeutics' price analysis, check to measure Halozyme Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Halozyme Therapeutics is operating at the current time. Most of Halozyme Therapeutics' value examination focuses on studying past and present price action to predict the probability of Halozyme Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Halozyme Therapeutics' price. Additionally, you may evaluate how the addition of Halozyme Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |
Is Halozyme Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Halozyme Therapeutics. If investors know Halozyme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Halozyme Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.546 | Earnings Share 2.1 | Revenue Per Share 6.286 | Quarterly Revenue Growth 0.267 | Return On Assets 0.1189 |
The market value of Halozyme Therapeutics is measured differently than its book value, which is the value of Halozyme that is recorded on the company's balance sheet. Investors also form their own opinion of Halozyme Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Halozyme Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Halozyme Therapeutics' market value can be influenced by many factors that don't directly affect Halozyme Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Halozyme Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Halozyme Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Halozyme Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.